Covering: 2008–2013. Previous review: 2008, 25, 475 There are a significant number of
natural product (NP) drugs in development. We review the 100 NP and NP-derived compounds …

Innate immune responses act as first line defences upon exposure to potentially noxious
stimuli. The innate immune system has evolved numerous intracellular and extracellular …

Target identification is a high-priority, albeit challenging, aspect of drug discovery. Diazirine-based
photoaffinity probes (PAPs) can facilitate the process by covalently capturing transient …

The NOD-like receptor (NLR) family, pyrin domain–containing protein 3 (NLRP3) inflammasome
is a component of the inflammatory process, and its aberrant activation is pathogenic in …

Human aging is associated with an increased frequency of somatic mutations in hematopoietic
cells. Several of these recurrent mutations, including those in the gene encoding the …

Background & Aims NOD-like receptor protein 3 (NLRP3) inflammasome activation occurs in
Non-alcoholic fatty liver disease (NAFLD). We used the first small molecule NLRP3 inhibitor…

Interleukin-1β (IL-1β) is a cytokine whose bioactivity is controlled by activation of the
inflammasome. However, in response to lipopolysaccharide, human monocytes secrete IL-1β …

Inhibition of the NLRP3 inflammasome is a promising strategy for the development of new
treatments for inflammatory diseases. MCC950 is a potent and specific small-molecule …

Parkinson’s disease (PD) is characterized by a profound loss of dopaminergic neurons in
the substantia nigra, accompanied by chronic neuroinflammation, mitochondrial dysfunction, …

Activation of the inflammasome is implicated in the pathogenesis of an increasing number
of inflammatory diseases, including Alzheimer’s disease (AD). Research reporting …